bullish
APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne
549 Views23 Feb 2025 00:30
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and collaborations to strengthen market position.
What is covered in the Full Insight:
- Ono Pharmaceutical FDA Approval
- Shionogi Digital Therapeutic Approval
- Samsung and Celltrion Biosimilar Approvals
- Potential US Tariffs Impact
- Upcoming Earnings and Events
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »- CSPC Pharmaceutical (1093 HK) - Earnings Decline Amid Pricing Pressure
- CSPC Pharmaceutical (1093 HK) - Legacy Products Faced Pricing Pressures
- CSPC Pharmaceutical (1093 HK) - Accelerating Growth in Finished Drug Sales
- CSPC Pharmaceutical (1093 HK): Deep Value High Dividend Yield Idea; New Launches to Drive Growth
- CSPC Pharmaceutical (1093 HK) - New Products to Contribute Meaningful Revenue in 2024
Trending Collections
More »Trending Insights
More »- Hang Seng Indexes: FAF Methodology Change for Secondary Listings; Over US$1bn to Buy in NetEase
- Korea Short Selling: Off to the Races
- Nikkei 225 Mar25 Rebal - A Big Buy With Buying Shadow, A Bigger Sell, And $2bn of Funding Flows
- [Japan Activism] - KKR and JIC Buy Out Topcon (7732 JP) At ¥3,300/Share
- Vesync (2148 HK): 23rd April Scheme Vote. Done Deal
Top Unpaywalled Insights
More »- Aiming for REITs with Lower Downside Risk and Expectations of Higher Shareholder Returns?
- Tariffs, Tapering, and Tectonic Shifts: Markets Brace for April | The New Barbarians #013
- APL Apollo Tubes (APAT IN) Stepping up the Gas on Capacity Expansions
- The LLM Quant Revolution: From ChatGPT to Wall Street
- The Fed's Next Move: How Interest Rates Will Make or Break Your Portfolio
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- APAC Healthcare Weekly (Mar 16)- Celltrion, Ono Pharma, Sun Pharma, Syngene, Zydus, Sichuan Kelun16 Mar 2025
- APAC Healthcare Weekly (Mar 9)- Daiichi Sankyo, Kyorin Pharma, Celltrion, Zydus Lifesciences, Biocon09 Mar 2025
- APAC Healthcare Weekly (Mar 2)- Celltrion, Samsung Biologics, Biocon, Zydus Life, Healthcare Global02 Mar 2025
- APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne23 Feb 2025
- APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin16 Feb 2025
- APAC Healthcare Weekly (Feb 9)- Daiichi Sankyo, Astellas, SanBio, IHH, Henlius Biotech, Dr. Reddy’s09 Feb 2025
- APAC Healthcare Weekly (Feb 2)- Daiichi Sankyo, Eisai, Nippon Shinyaku, Shionogi, Celltrion02 Feb 2025
x